CA-USERTESTING
27.1.2021 03:02:09 CET | Business Wire | Press release
Collecting fast customer feedback has become mission-critical when competing in what is a very new and different business world. The ability to empathize with customers and understand how their buying behaviors have changed has never been more important than it is today. UserTesting , a leading provider of on-demand human insight , today announced several new capabilities designed to help companies meet the ever-evolving needs of their customers, with more test types that can give a greater understanding of how they organize and prioritize information, and interpret experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005448/en/
The January 2021 Product Release includes new test types for both web and mobile experiences, plus interactive visualization capabilities in the form of click maps, designed to reduce the amount of time it takes to review and analyze data.
With UserTesting’s latest release, companies can:
Understand how customers organize information and prioritize needs to deliver what they want
Card sorting helps users group, label, and describe information more effectively. UserTesting customers can now run closed, open, and hybrid card sort tests to gather insight into how to organize content and optimize their information architecture. With card sorting, companies can now more easily build experiences that put the customers’ needs first and make it easier for them to find what it is they want.
The prioritization matrix provides objective evidence to help teams prioritize tasks and projects. Not only does this reduce organizational risk by ensuring teams use customer feedback to focus on the most important tasks, but it also helps teams gain internal alignment faster with unbiased feedback directly from customers.
Leverage new test types to understand how your product, digital, and mobile iOS app experiences are resonating with customers
Developers can gather feedback on ease-of-use and perceived value before releasing apps on the App Store® online store with support for TestFlight® software public links. We’ve made it possible for you to do so with zero modifications to your project, zero lines of code, and zero configuration. Any team can easily gather qualitative feedback from real customers while they record their entire mobile screen - providing valuable input into how users interact with your app, and where you can optimize the experience.
System usability scale plus (SUS+) helps companies evaluate the usability of a product through a standardized template. This enables tracking improvements over time with longitudinal studies or easily comparing product usability to competitive products. Optional questions also allow users to measure promoter score and adjective rating.
Save time during post-test analysis with powerful and interactive visualizations
Click maps provide an interactive visual representation of all participant clicks and inputs on websites and hosted prototypes. This saves time during post-test analysis by helping companies quickly evaluate critical site interactions and then drill down further to get additional context and watch customers explain their thought process as they complete tasks and navigate sites.
"Companies are having to change and adapt at record speeds. The shift to a digital-first strategy, combined with rapidly changing consumer sentiment, has made collecting customer feedback vital to the process of designing, building, and marketing experiences,” said Kaj van de Loo, CTO at UserTesting. "Our latest offerings focus on empowering product managers, marketers, UX researchers, and designers with the tools to help them collect, prioritize, and analyze feedback so that they can build experiences that resonate with their customers, even when customer attitudes and behaviors are rapidly changing.”
Credit Notice
App Store® and TestFlight® are registered trademarks of Apple Inc.
About UserTesting
UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers including more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom